and some pharmacological agents is also described.
An important strategy for inherited degeneration is to replace non-functional proteins, although this may not be an effective approach in autosomal dominant disease. A more generic option would be to manipulate the machinery controlling apoptosis by, for instance, over expressing genes such as bcl-2 which protects from apoptosis, or reducing the expression of a gene such as p53 which is known to be important in the execution of the apoptotic programme in some cell-insult combinations. 15.16 The appeal of interfering with the apoptotic pathway is that, given the ubiquity of apoptosis in chronic cell death, a single therapy might be effective for a very large number of conditions. Unfortunately, therapies operating so far downstream may be acting too late to do anything other than temporarily slow disease, and in early studies this appears to be the case. Similarly, bFGF is effective in photoreceptor rescue in the RCS and light-damaged rats but as yet no effect has been demonstrated in the rd mouse. There is also an impression that the retinal ganglion cells appear to be better protected by BDNF, whilst the photoreceptors appear to be better protected by bFGF and CNTF. 
Pharmacological photoreceptor cell rescue
Gene therapy and transplantation offer great potential in the future, but it may be that pharmacological intervention may be more practical, especially in the short to medium term. As mentioned above, ion channel blockers have been reported to have some benefit58 and manipulation of dopaminergic pathways may also be of value.59 It may also be possible to manipulate growth factor levels indirectly by pharmacological means.
Recently, it has been shown that a-adrenergic drugs can increase retinal bFGF60 and protect against light damage.
Conclusions
To date, despite enormous efforts, clinical success in the protection of central and peripheral neurons from genetic abnormalities or acquired insults has been limited. There is, however, now reason to believe that we are on the threshold of seeing effective, novel therapeutic strategies being implemented in the clinic.
